Angela Boyhan joins Norgine
This article was originally published in Scrip
Dr Angela Boyhan has joined the European speciality pharmaceutical company Norgineas director of evaluation and alliances. Dr Boyhan was most recently project and portfolio manager of the Oncology Commercial Centre of Excellence, where she was responsible for project management of oncology product launches in Europe and oncology portfolio management. She previously held roles as project manager and leader at GlaxoSmithKline, leading product development teams across different stages of development in neurology, infectious diseases and oncology.
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.